You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

noncontiguous stage II adult immunoblastic large cell lymphoma

Showing 26 - 50 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Contiguous Stage II Mantle Cell Lymphoma, Noncontiguous Stage II Mantle Cell Lymphoma, Recurrent Mantle Cell Lymphoma Trial in

Completed
Has Results
  • Contiguous Stage II Mantle Cell Lymphoma
  • +5 more
  • Duarte, California
  • +1 more
Jan 12, 2022

Aggressive B-Cell Non-Hodgkin Lymphoma, Ann Arbor Stage III Grade 2 Follicular Lymphoma, Ann Arbor Stage III Grade 3 Follicular

Recruiting
  • Aggressive B-Cell Non-Hodgkin Lymphoma
  • +19 more
  • CD47 Antagonist ALX148
  • +2 more
  • Houston, Texas
    M D Anderson Cancer Center
Aug 9, 2022

T Cell Non-Hodgkin Lymphoma, Peripheral T-Cell Lymphoma, Not Otherwise Specified, Angioimmunoblastic T-cell Lymphoma Trial in

Recruiting
  • T Cell Non-Hodgkin Lymphoma
  • +3 more
  • AUTO4
  • Barcelona, Spain
  • +4 more
Feb 1, 2022

Lymphoma Trial in Scottsdale, Jacksonville, Rochester (biological, drug, genetic, other)

Active, not recruiting
  • Lymphoma
  • pegfilgrastim
  • +8 more
  • Scottsdale, Arizona
  • +2 more
Jan 7, 2022

Ann Arbor Stage II DLBCL, Ann Arbor Stage II Follicular Lymphoma, Ann Arbor Stage II Marginal Zone Lymphoma Trial in Scottsdale,

Recruiting
  • Ann Arbor Stage II Diffuse Large B-Cell Lymphoma
  • +13 more
  • Scottsdale, Arizona
  • +2 more
Jun 1, 2022

Peripheral T Cell Lymphoma, PTCL, Extranodal NK/T-cell Lymphoma Trial in Worldwide (Tislelizumab)

Completed
Has Results
  • Peripheral T Cell Lymphoma
  • +18 more
  • Vancouver, British Columbia, Canada
  • +29 more
Apr 29, 2022

Advanced Primary Cutaneous T-Cell Non-Hodgkin Lymphoma, Recurrent Angioimmunoblastic T-Cell Lymphoma, Recurrent Grade 1

Active, not recruiting
  • Advanced Primary Cutaneous T-Cell Non-Hodgkin Lymphoma
  • +18 more
  • Anti-ICOS Monoclonal Antibody MEDI-570
  • +2 more
  • Duarte, California
  • +22 more
Jan 18, 2023

Adult Diffuse Large Cell Lymphoma, Recurrent, Adult Refractory DLBCL Trial in Canada (DPX-Survivac, Pembrolizumab,

Active, not recruiting
  • Adult Diffuse Large Cell Lymphoma
  • +2 more
  • DPX-Survivac
  • +2 more
  • Calgary, Alberta, Canada
  • +5 more
Nov 9, 2022

AIDS-Related Plasmablastic Lymphoma, AIDS-Related Primary Effusion Lymphoma, Ann Arbor Stage I DLBCL Trial in United States

Completed
Has Results
  • AIDS-Related Plasmablastic Lymphoma
  • +15 more
  • Montgomery, Alabama
  • +34 more
Feb 23, 2022

Acute Biphenotypic Leukemia, Acute Erythroid Leukemia in Remission, Acute Leukemia in Remission Trial in Seattle (drug,

Terminated
Has Results
  • Acute Biphenotypic Leukemia
  • +29 more
  • Seattle, Washington
    Fred Hutch/University of Washington Cancer Consortium
Jan 4, 2023

CD20 Positive, Recurrent DLBCL, Refractory DLBCL Trial in Buffalo (drug, other, biological)

Active, not recruiting
Has Results
  • CD20 Positive
  • +6 more
  • Buffalo, New York
    Roswell Park Cancer Institute
Oct 11, 2021

Contiguous Stage II Small Lymphocytic Lymphoma, Noncontiguous Stage II Small Lymphocytic Lymphoma, Prolymphocytic Leukemia Trial

Active, not recruiting
  • Contiguous Stage II Small Lymphocytic Lymphoma
  • +11 more
  • MOR00208
  • +2 more
  • Columbus, Ohio
    The Ohio State University Comprehensive Cancer Center
Feb 24, 2022

Ann Arbor Stage I Primary Mediastinal (Thymic) Large B-Cell Lymphoma, Ann Arbor Stage II Primary Mediastinal (Thymic) Large

Recruiting
  • Ann Arbor Stage I Primary Mediastinal (Thymic) Large B-Cell Lymphoma
  • +3 more
  • Brentuximab Vedotin
  • +6 more
  • Houston, Texas
    M D Anderson Cancer Center
Feb 10, 2022

Brain and CNS Tumors, Chronic Myeloproliferative Disorders, Leukemia Trial in Detroit (3'-deoxy-3'-[18F]fluorothymidine)

Recruiting
  • Brain and Central Nervous System Tumors
  • +8 more
  • 3'-deoxy-3'-[18F]fluorothymidine
  • Detroit, Michigan
    Barbara Ann Karmanos Cancer Institute
Mar 30, 2022

Ann Arbor Stage III DLBCL, Ann Arbor Stage IIX (Bulky) DLBCL, Ann Arbor Stage IV DLBCL Trial in United States (drug, other,

Suspended
  • Ann Arbor Stage III Diffuse Large B-Cell Lymphoma
  • +20 more
  • Tucson, Arizona
  • +110 more
Jan 31, 2023

Diffuse Large B-cell Lymphoma (DLBCL) Trial in Worldwide (CTL019)

Completed
  • Diffuse Large B-cell Lymphoma (DLBCL)
  • Tisagenlecleucel
  • Lymphodepleting chemotherapy
  • San Francisco, California
  • +25 more
Jan 27, 2023

Lymphoma Trial in Worldwide (immunoscintigraphy, technetium Tc 99m epratuzumab)

Unknown status
  • Lymphoma
  • immunoscintigraphy
  • technetium Tc 99m epratuzumab
  • Los Angeles, California
  • +7 more
Aug 12, 2021

Lymphoma Trial in Worldwide (immunoscintigraphy, technetium Tc 99m epratuzumab)

Unknown status
  • Lymphoma
  • immunoscintigraphy
  • technetium Tc 99m epratuzumab
  • Los Angeles, California
  • +7 more
Aug 12, 2021

Myelodysplastic Syndrome, Previously Treated Myelodysplastic Syndrome, Recurrent Adult Acute Myeloid Leukemia Trial in

Recruiting
  • Myelodysplastic Syndrome
  • +16 more
  • Computed Tomography
  • +6 more
  • Scottsdale, Arizona
  • +2 more
Feb 3, 2022

Malignant Non-Hodgkin Lymphomas Trial in Berne (CD34+ cell selection)

Active, not recruiting
  • Malignant Non-Hodgkin Lymphomas
  • CD34+ cell selection
  • Berne, Switzerland
    Department for Medical Oncology; University Hospital/Inselspital
Jul 29, 2021

Lymphoma Trial (pegfilgrastim, rituximab, cyclophosphamide)

Completed
  • Lymphoma
  • pegfilgrastim
  • +5 more
  • (no location specified)
Jul 2, 2021

Burkitt Lymphoma, Diffuse Large B-cell Lymphoma, c-MYC Positive, Plasmablastic Lymphoma Trial in United States (EPOCH-R,

Active, not recruiting
Has Results
  • Burkitt Lymphoma
  • +2 more
  • La Jolla, California
  • +29 more
Nov 2, 2021

Tissue, Blood, and Body Fluid Sample Collection From Hematologic

Recruiting
  • Chronic Myeloproliferative Disorders
  • +7 more
  • biologic sample preservation procedure
  • cytology specimen collection procedure
  • Chapel Hill, North Carolina
    Lineberger Comprehensive Cancer Center at University of North Ca
Oct 14, 2021

Adult Nasal Type Extranodal NK/T-cell Lymphoma, Anaplastic Large Cell Lymphoma, Angioimmunoblastic T-cell Lymphoma Trial in

Completed
Has Results
  • Adult Nasal Type Extranodal NK/T-cell Lymphoma
  • +35 more
  • Akt inhibitor MK2206
  • laboratory biomarker analysis
  • Houston, Texas
    M D Anderson Cancer Center
Oct 14, 2020

Contiguous Stage II Mantle Cell Lymphoma, Noncontiguous Stage II Mantle Cell Lymphoma, Stage I Mantle Cell Lymphoma Trial in

Active, not recruiting
  • Contiguous Stage II Mantle Cell Lymphoma
  • +4 more
  • Chicago, Illinois
  • +4 more
Apr 30, 2021